NANOBIOTIX Stock: +5.64% at Opening, Rebound After Monday's Decline
This morning, the French biotech stock is regaining ground at the Paris Stock Exchange, showing a clear recovery after a strongly bearish session at the start of the week.
Morning Recovery and Weekly Overview
Nanobiotix exhibited a 5.64% increase at opening this morning, reaching €17.98. This rise corresponds to a reduction in selling pressure observed last Monday, which had resulted in a 11.96% loss for the stock. Over a full week, the movement remains limited to +0.45%, revealing some indecision among investors. Trading volume remains moderate, with only 0.21% of the capital traded, indicating limited participation in the rebound. Over a longer horizon, the stock maintains its remarkable momentum: +183.1% over three months and +354.7% over the past twelve months, a performance that strongly contrasts with the CAC 40, which has increased by 9.6% annually. This morning, the benchmark Paris index gained 1.17%, providing a slightly favorable market context for the stock.
Technical Analysis and Market Dynamics
Technically, the dynamics remain mixed. The stock is now above its 50-day moving average, currently at €14.96, which forms a first solid support zone. It also performs well above its 200-day average, set at €6.85, reflecting its significant progress since the beginning of the year. The Relative Strength Index, positioned at 36, indicates some technical weakness without a clear signal of imminent recovery. The stochastic oscillator sends a sell signal, reinforcing this caution. In the short term, the stock encounters resistance at €24.45, while technical support is anchored at €13.36, thus offering a fluctuation corridor of about €11 on either side of its current price.
Further Technical Indicators and Volatility
The MACD shows a negative setup, with its main line at -€0.08 below the signal line at €0.24, while the histogram is set at -€0.32, indicating persistence of underlying bearish pressure. The Chaikin Money Flow, measured at -0.16, also points towards a drainage of buying flows. These indicators suggest that the rebound observed this morning is more a part of technical consolidation rather than an established trend reversal. Monthly volatility remains high at 36.60%, reflecting the wide movements of the stock, while its beta of -0.25 indicates a very low correlation with general market movements, a typical characteristic of stocks in advanced clinical stages.
